WAVE Life Sciences Ltd.
WVE
$6.59
$0.0450.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.06% | -4.42% | -37.29% | 202.25% | 661.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.06% | -4.42% | -37.29% | 202.25% | 661.49% |
| Cost of Revenue | 25.95% | 22.82% | 17.40% | 13.51% | 10.98% |
| Gross Profit | -216.51% | -207.59% | -129.98% | 66.37% | 81.29% |
| SG&A Expenses | 21.34% | 15.07% | 10.12% | 9.64% | 4.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.64% | 20.63% | 15.30% | 12.39% | 9.04% |
| Operating Income | -74.24% | -62.37% | -63.71% | 38.56% | 53.41% |
| Income Before Tax | -80.18% | -66.71% | -67.74% | 43.19% | 58.64% |
| Income Tax Expenses | -- | -- | -100.00% | -199.41% | -199.41% |
| Earnings from Continuing Operations | -82.16% | -68.67% | -67.73% | 44.00% | 59.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.16% | -68.67% | -67.73% | 44.00% | 59.27% |
| EBIT | -74.24% | -62.37% | -63.71% | 38.56% | 53.41% |
| EBITDA | -80.61% | -69.07% | -69.23% | 39.11% | 54.55% |
| EPS Basic | -57.17% | -42.17% | -28.24% | 56.96% | 70.26% |
| Normalized Basic EPS | -56.00% | -41.18% | -28.75% | 56.43% | 69.90% |
| EPS Diluted | -58.40% | -43.46% | -29.22% | 56.77% | 70.08% |
| Normalized Diluted EPS | -57.95% | -43.06% | -28.65% | 56.38% | 69.86% |
| Average Basic Shares Outstanding | 30.13% | 30.64% | 22.93% | 19.99% | 26.36% |
| Average Diluted Shares Outstanding | 32.25% | 32.90% | 22.64% | 20.23% | 26.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |